CTLA4 and neoplasm: In a pre-clinical study of colorectal cancer, it was demonstrated that HBI-8000 – a HDACi- augmented the treatment outcome in synergy with CTLA4/PD-1/PD-L1 blockade and resulted in improved tumor growth control (143).